Moscow, Russia
Valenta Pharmaceuticals is a leading pharmaceutical company in Russia, ranking in the top three nationwide. With a wide range of over 30 medicines, the company specializes in various therapeutic areas including psychoneurology, urology, gastroenterology, and general practice. Notable brands include Ingavirin, Grammidin, Trimedat, Phenotropil, Phenazepam, and Pantocalcin. Valenta's commitment to innovation is evident through its ongoing research and development activities and product registration processes.
Operating its own production facilities in the Moscow region, the company is dedicated to implementing advanced manufacturing projects. Plans for a new state-of-the-art plant, set to open in 2016, highlight Valenta's commitment to maintaining a cutting-edge presence in the Russian pharmaceutical market. The company's focus on social responsibility is underscored by its dedication to providing high-quality and effective healthcare solutions to patients and healthcare professionals.
With over 1300 employees across Russia, Valenta is focused on developing the Russian healthcare system and advancing medical science. The company offers an attractive compensation package, including competitive salaries, annual bonuses, corporate transport, mobile coverage, and medical insurance. Educational and motivational programs are also provided at all corporate levels, emphasizing career development opportunities. The corporate culture of Valenta Pharmaceuticals is rooted in values such as respect, openness, and transparency, providing an engaging work environment for its employees.
Overall, Valenta Pharmaceuticals presents an appealing investment opportunity, given its strong position as a key player in the Russian pharmaceutical market, ongoing expansion plans, and commitment to innovation and social responsibility.
